Filter Results:
(30)
Show Results For
- All HBS Web
(125)
- Faculty Publications (30)
Show Results For
- All HBS Web
(125)
- Faculty Publications (30)
←
Page 2 of 30
Results
- January 2011 (Revised January 2012)
- Case
The Case of the Unidentified Healthcare Companies2010
By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Bohmer, Richard, Ethan Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010." Harvard Business School Case 611-043, January 2011. (Revised January 2012.)
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- November 2007
- Class Lecture
The Baby Business (FSS)
By: Debora L. Spar
In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry
Spar, Debora L. "The Baby Business (FSS)." Harvard Business School Class Lecture 708-701, November 2007.
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details
Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; United States
Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Biotechnology Industry; Cambridge
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (A)." Harvard Business School Case 600-038, December 1999. (Revised August 2001.)
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)